Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xeris Biopharma Holdings (XERS) Consolidated Net Income: 2020-2025

Historic Consolidated Net Income for Xeris Biopharma Holdings (XERS) over the last 5 years, with Sep 2025 value amounting to $621,000.

  • Xeris Biopharma Holdings' Consolidated Net Income rose 103.95% to $621,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$15.6 million, marking a year-over-year increase of 75.22%. This contributed to the annual value of -$54.8 million for FY2024, which is 11.92% up from last year.
  • As of Q3 2025, Xeris Biopharma Holdings' Consolidated Net Income stood at $621,000, which was up 132.21% from -$1.9 million recorded in Q2 2025.
  • Xeris Biopharma Holdings' 5-year Consolidated Net Income high stood at $621,000 for Q3 2025, and its period low was -$50.8 million during Q4 2021.
  • Moreover, its 3-year median value for Consolidated Net Income was -$13.4 million (2023), whereas its average is -$11.6 million.
  • Its Consolidated Net Income has fluctuated over the past 5 years, first crashed by 132.37% in 2021, then skyrocketed by 103.95% in 2025.
  • Over the past 5 years, Xeris Biopharma Holdings' Consolidated Net Income (Quarterly) stood at -$50.8 million in 2021, then spiked by 74.54% to -$12.9 million in 2022, then dropped by 3.56% to -$13.4 million in 2023, then surged by 61.81% to -$5.1 million in 2024, then soared by 103.95% to $621,000 in 2025.
  • Its Consolidated Net Income was $621,000 in Q3 2025, compared to -$1.9 million in Q2 2025 and -$9.2 million in Q1 2025.